877-202-0205     support@chemchart.com     @chemchart
        
Sign In    Register
   Reset Filters

Typical antipsychotics, D2 antagonists

Categories

Antipsychotics (4)
Cyclic compounds (4)
Dopamine antagonists (4)
Drugs acting on the nervous system (4)
Psychoactive drugs (4)
Psychopharmacology (4)
Aromatic compounds (3)
Fluoroarenes (3)
D3 antagonists (2)
D4 antagonists (2)
Drugs acting on the cardiovascular system (2)
Pharmaceuticals (2)
Alkenes (1)
Allyl compounds (1)
Alpha blockers (1)
Alpha-1 blockers (1)
Alpha-2 blockers (1)
Antiarrhythmic agents (1)
Antihypertensive agents (1)
Diphenylbutylpiperidines (1)
Drugs acting on the genito-urinary system (1)
Drugs for benign prostatic hyperplasia (1)
Five-membered rings (1)
Piperidines (1)
Potassium channel blockers (1)
Pyrrolidines (1)
Six-membered rings (1)
Spiro compounds (1)
Ureas (1)
Urologicals (1)

Suppliers

Sigma Aldrich (3)

pimozide (2062-78-4)  
Orap  ·  Antalon  ·  Orap forte
Pimozide (sold under the brand name Orap) is an antipsychotic drug of the diphenylbutylpiperidine class. It was discovered at Janssen Pharmaceutica in 1963. It has a high potency compared to chlorpromazine (ratio 50-70:1).
Pipamperone (1893-33-0)  
R 3345  ·  Dipiperon  ·  1'-(3-(4-fluorobenzoyl)propyl)-(1,4'-bipiperidine) -4'-carboxamide
Pipamperone (INN, USAN, BAN), also known as carpiperone and floropipamide or fluoropipamide, and as floropipamide hydrochloride (JAN), is a typical antipsychotic of the butyrophenone family used in the treatment of schizophrenia. It is or has been marketed under brand names including Dipiperon, Dipiperal, Piperonil, Piperonyl, and Propitan. Pipamperone was discovered at Janssen Pharmaceutica in 1961, and entered clinical trials in the United States in 1963.
spiperone (749-02-0)  
Spiroperidol  ·  Spiroperone
Spiperone (Spiroperidol; brand name: Spiropitan (JP)) is a typical antipsychotic and research chemical belonging to the butyrophenone chemical class. It is licensed for clinical use in Japan as a treatment for schizophrenia. Additionally, spiperone was identified by compound screening to be an activator of Ca2+ activated Cl− channels (CaCCs), thus a potential target for therapy of cystic fibrosis.
Related searches
Typical antipsychotics
D2 antagonists